Freenome
Investors React to Initial Data on Freenome's Blood-Based Colon Cancer Detection Test
The company's trial results fell short of what some investors had predicted, easing competition concerns for both Guardant Health and Exact Sciences.
Freenome Launches Prospective Study for Blood-Based Lung Cancer Screening Test
The PROACT LUNG observational trial will recruit up to 20,000 individuals eligible for annual imaging-based screening and will assess the test's performance in comparison.
Freenome, Walgreens Partner to Diversify Cancer Early Detection Studies
The pharmacy firm will lend its recruitment technology and infrastructure to enroll a more diverse patient population, beginning with Freenome's Sanderson Study.
Freenome Partners With Geisinger to Recruit Patients for Multi-Cancer Screening Study
The Pennsylvania health system will be able to access patients in both urban and rural settings, aiding Freenome's goal to recruit a total of 8,000 individuals.
Freenome Launches Multi-Cancer Detection Study Using Multiomics, Real-World Evidence
The company plans to analyze both traditional and real-world data from about 8,000 individuals to validate and optimize its multi-cancer early detection platform.